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OBJECTIVE: Determine whether physicians spend more time
with patients prescribed high-risk medications—-anticoagulants,
anticonvulsants, antiarrythmics, antidiabetics and beta ago-
nists—-that require either additional patient education about
correct use and adverse effects or increased monitoring by
providers. METHODS: Patient visit data to physicians from the
2003 National Ambulatory Medical Care Survey (n = 17,078)
were used in multiple regression (SPSS 12.0, á = 0.05). Visit time
was the dependent variable. Independent variables included indi-
cator variables for prescribing each high-risk medication and
visit circumstances hypothesized to require more time—1)
patient was new to the practice; 2); patient’s condition was new;
and 3) physician was not the patient’s primary physician. Inter-
actions between high risk medication prescribing and visit cir-
cumstances were also examined. Control variables included
modiﬁed Charlson index, diagnostic and counseling services pro-
vided, patient and provider demographics. RESULTS: Visits
lasted an average of 19 minutes. Signiﬁcantly higher visit times
were found for patients prescribed either anticonvulsants, anti-
coagulants or antidiabetics. Visit times were additionally higher
if 1) the condition was new and the patient was prescribed anti-
convulsants or antidiabetics, or 2) the patient was new to the
practice and was prescribed anticonvulsants. Patients not seeing
their primary physician had lower visit times if they were pre-
scribed anticoagulants or antidiabetics. No visit time increases
were associated with antiarrythmics or beta agonists. CON-
CLUSION: Visit times increased with the prescribing of certain
high-risk medications in our study and during certain visit cir-
cumstances. However, increases were not uniformly found across
all high-risk medications examined. This gap in care suggests
that less expensive healthcare providers like pharmacists are
needed to enter into collaborative working relationships with
physicians to provide counseling, education and monitoring for
these medications.
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INFECTION—Clinical Outcomes Studies
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HEPATOTOXICITY ASSOCIATED WITH RIFAMPIN AND
PYRAZINAMIDE THERAPY OF LATENT TUBERCULOSIS
INFECTION:A META-ANALYSIS
Ghosh S
University of Louisiana at Monroe, Monroe, LA, USA
OBJECTIVES: Observational studies individually don’t shed
much light on the association of hepatotoxicity with rifampin
and pyrazinamide (RPZ) therapy .The following a priori
hypotheses were tested : 1) Every study will have an effect size
greater than one; 2) Effect size will vary depending on head count
for various risk factors; 3) Intensive monitoring of RPZ therapy
reduce hepatotoxicity. In addition to research hypotheses the fol-
lowing research questions were identiﬁed: 1) Who are at greater
risk of having hepatotoxicity; 2) Is alcohol an effect modiﬁer or
a confounder? METHODS: For this research only the observa-
tional studies were selected. Electronic searches of MEDLINE
(1980 to Aug 2005) were carried out to identify relevant papers.
An instrument was devised to assess the quality of the selected
studies which measures the quality of the study in range of
1–10.Consistency of the items included in the instrument was
described by Cronbach’s á (0.7). Review Manager 4.2 (Cochrane
Collaboration Center) used to do the meta-analysis. Regression
analysis was performed to ﬁnd relationship between effect size
and certain risk factors. RESULTS: The odd ratio of the pooled
data is 2.98(2.16–4.11). One of the studies has an effect size of
0.71(0.22–2.27). The odd ratio for risk factors are: liver disease-
5.14(1.64–16.10); race-1.85(0.88–3.91); gender-1.66(0.87–
3.15); alcohol-1.51(0.82–2.75); age-1.15(0.51–2.62). The odd
ratios across the alcoholics and non alcoholics strata are equal.
The odd ratio of hepatotoxicity is 0.54(0.21–1.37) among
patients who underwent intensive monitoring of RPZ therapy.
The R square of the regression for the relationship between effect
size, female and non blacks is 0.94. CONCLUSIONS: The meta-
analysis of data shows that RPZ users are at higher odd of having
hepatotoxicity. The effect size is related to number of female and
non black patients included. Female, older, black, and alcoholic
are at higher risk. Alcohol is a confounder. Monitoring does
reduce the cases of hepatotoxicity.
INFECTION—Cost Studies
PIN2
COST COMPARISON OF A ONCE-DAILY PARENTERAL
ANTIBIOTIC IN HOSPITAL SETTINGS: INFORMATION FROM
THE SIDESTEP STUDY
Turpin RS1,Tice A2,Wu JH1,Taylor S1, Polis A1,Abramson M1
1Merck & Co., Inc, West Point, PA, USA, 2University of Hawaii,
Honolulu, HI, USA
OBJECTIVES: Diabetic foot infections (DFI) account for more
hospital days than any diabetes-related diagnosis. Many patients
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